MannKind Co. (NASDAQ:MNKD) Shares Sold by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL reduced its stake in shares of MannKind Co. (NASDAQ:MNKD) by 45.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,382 shares of the biopharmaceutical company’s stock after selling 64,087 shares during the quarter. Tudor Investment Corp ET AL’s holdings in MannKind were worth $504,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Jones Financial Companies Lllp increased its position in shares of MannKind by 3,294.8% during the fourth quarter. Jones Financial Companies Lllp now owns 6,586 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 6,392 shares in the last quarter. Kovitz Investment Group Partners LLC acquired a new position in MannKind during the fourth quarter worth approximately $65,000. Beirne Wealth Consulting Services LLC purchased a new stake in MannKind in the fourth quarter valued at approximately $66,000. Proficio Capital Partners LLC acquired a new stake in shares of MannKind in the fourth quarter valued at approximately $70,000. Finally, Marshall Investment Management LLC purchased a new position in shares of MannKind during the fourth quarter worth approximately $69,000. 49.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on MNKD. StockNews.com upgraded shares of MannKind from a “hold” rating to a “buy” rating in a research note on Wednesday, March 19th. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of MannKind in a research note on Thursday, February 27th. Finally, Mizuho started coverage on MannKind in a research note on Thursday, April 10th. They set an “outperform” rating and a $12.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, MannKind presently has an average rating of “Buy” and a consensus price target of $9.56.

MannKind Price Performance

Shares of MNKD stock opened at $4.64 on Friday. The business’s fifty day moving average price is $4.90 and its 200 day moving average price is $5.84. The firm has a market capitalization of $1.41 billion, a PE ratio of 66.21 and a beta of 1.14. MannKind Co. has a 1-year low of $4.17 and a 1-year high of $7.63.

MannKind (NASDAQ:MNKD) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. The business had revenue of $78.35 million during the quarter, compared to the consensus estimate of $75.86 million. MannKind had a net margin of 8.07% and a negative return on equity of 17.74%. The business’s revenue was up 18.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.05 EPS. Equities research analysts expect that MannKind Co. will post 0.1 earnings per share for the current fiscal year.

MannKind Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.